articleThe Journal of Prevention of Alzheimer s DiseaseMar 22, 2023DIAMOND OA

Lecanemab: Appropriate Use Recommendations

JCJ CummingsLAL ApostolovaGDG D RabinoviciAAA AtriPAPau Aisen

Cummings Foundation

PubMed
Indexed incrossrefdoajpubmed

Abstract

Lecanemab (Leqembi®) is approved in the United States for the treatment of Alzheimer's disease (AD) to be initiated in early AD (mild cognitive impairment [MCI] due to AD or mild AD dementia) with confirmed brain amyloid pathology. Appropriate Use Recommendations (AURs) are intended to help guide the introduction of new therapies into real-world clinical practice. Community dwelling patients with AD differ from those participating in clinical trials. Administration of lecanemab at clinical trial sites by individuals experienced with monoclonal antibody therapy also differs from the community clinic-based administration of lecanemab. These AURs use clinical trial data as well as research and care information…

Citation impact

774
total citations
FWCI
424.98
Percentile
100%
References
65
Citations per year

Authors

11

Topics & keywords

Topics
Keywords
  • Medicine
  • Clinical trial
  • Dementia
  • Adverse effect
  • Asymptomatic
  • Disease
  • Intensive care medicine
  • Internal medicine
UN Sustainable Development Goals
  • Reduced inequalities
No related works found for this paper.

Funding